Eli Lilly CEO on drug that could aid Covid-19 recovery when paired with remdesivir

Eli Lilly said on Monday its rheumatoid arthritis drug baricitinib shortened the time to recover from Covid-19 in hospitalized patients when taken in combination with Gilead Sciences' antiviral remdesivir. Eli Lilly CEO David Ricks joined "Squawk Box" to discuss.
Mon, Sep 14 202010:43 AM EDT